Department of Neurology Osaka University Graduate School Medicine Osaka Japan.
Department of Neurology Osaka General Medical Center Osaka Japan.
J Am Heart Assoc. 2023 Aug;12(15):e029618. doi: 10.1161/JAHA.123.029618. Epub 2023 Jul 25.
Background Limited data exist on the prognostic factors for patients with ischemic stroke and active cancer. Methods and Results We conducted a prospective, multicenter, observational study in Japan, including patients with acute ischemic stroke and active cancer, to investigate the prognostic factors. We followed up the patients for 1 year after stroke onset. The patients were divided into 2 groups according to cryptogenic stroke and known causes (small-vessel occlusion, large-artery atherosclerosis, cardioembolism, and other determined cause), and survival was compared. The hazard ratios (HRs) and 95% CIs for mortality were calculated using Cox regression models. We identified 135 eligible patients (39% women; median age, 75 years). Of these patients, 51% had distant metastasis. A total of 65 (48%) and 70 (52%) patients had cryptogenic stroke and known causes, respectively. Patients with cryptogenic stroke had significantly shorter survival than those with known causes (HR [95% CI], 3.11 [1.82-5.32]). The multivariable Cox regression analysis revealed that distant metastasis, plasma D-dimer levels, venous thromboembolism (either deep venous thrombosis or pulmonary embolism) complications at stroke onset were independent predictors of mortality after adjusting for potential confounders. Cryptogenic stroke was associated with prognosis in univariable analysis but was not significant in multivariable analysis. The plasma D-dimer levels stratified the prognosis of patients with ischemic stroke and active cancer. Conclusions The prognosis of patients with acute ischemic stroke and active cancer varied considerably depending on stroke mechanism, distant metastasis, and coagulation abnormalities. The present study confirmed that coagulation abnormalities were crucial in determining the prognosis of such patients.
目前关于伴有活动期癌症的缺血性脑卒中患者的预后因素的数据有限。
我们在日本开展了一项前瞻性、多中心、观察性研究,纳入了急性缺血性脑卒中且伴有活动期癌症的患者,以探究其预后因素。我们在脑卒中发病后随访患者 1 年。根据隐源性卒中和已知病因(小血管闭塞、大动脉粥样硬化、心源性栓塞和其他明确病因)将患者分为 2 组,并比较其生存情况。采用 Cox 回归模型计算死亡率的风险比(HR)和 95%置信区间(CI)。我们共纳入 135 例符合条件的患者(39%为女性;中位年龄 75 岁)。其中 51%的患者存在远处转移。65 例(48%)和 70 例(52%)患者分别为隐源性卒中和已知病因。隐源性卒中患者的生存时间显著短于已知病因患者(HR[95%CI]:3.11[1.82-5.32])。多变量 Cox 回归分析显示,远处转移、发病时的血浆 D-二聚体水平、静脉血栓栓塞(深静脉血栓形成或肺栓塞)并发症是调整潜在混杂因素后死亡的独立预测因素。隐源性卒中有预后预测作用,但在多变量分析中无统计学意义。血浆 D-二聚体水平分层了伴有活动期癌症的缺血性脑卒中患者的预后。
急性缺血性脑卒中且伴有活动期癌症患者的预后差异较大,取决于脑卒中机制、远处转移和凝血异常。本研究证实凝血异常对这类患者的预后有重要影响。